The continued growth of Technophage from a small biotech into a clinical-stage biopharma has resulted in the company making the Financial Times’ 1000 Fastest Growing Companies in Europe for the in 2022. This rating is co-created by the Financial Times and Statista, who conducted months of diligent research and directly contacted tens of thousands of companies.

Our company is set for further growth in 2023 with plans of expansion, and a roadmap of major product developments, further improving its pipeline products until market.